An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
BACKGROUND
Acromegaly is a chronic disease impacting on morbidity and mortality. Increased mortality is reverted after the achievement of hormonal targets. The relative role of treatment options is still matter of debate.


METHODS
A retrospective chart review was performed on all the acromegalic patients attending our center along the last 20 years.


RESULTS
Data about 159 patients (83 F) were retrieved and analyzed: 18% had been lost to follow-up, while follow-up was >5 years in 79%. Growth hormone (GH) at diagnosis was 24 microg/L (median, range 3-239). Pituitary MRI showed a macro-, micro-adenoma or no lesion in 73.6, 22.9, and 3.5%, respectively. Hyperprolactinemia (hyperPRL) was present in 20.8%. Ninety-six and 29 patients had been treated by neurosurgery (NS) and irradiated (RT), respectively. Drugs had been employed in 149 patients (in 58 as the only treatment). At the last evaluation, 22% of patients were cured (hypopituitarism and GH deficiency in 6.3%), 37.1% were controlled by ongoing pharmacological treatment, 22.6% had discordant GH and Insulin-like growth factor I (IGF-I) values, and 18.2% had still active disease (median follow-up in this last group was 9 months). By evaluating the outcome with a multimodal approach, safe GH and normal IGF-I had been achieved in 78 and 63.5% of the whole series, 80.5 and 59.7% in patients submitted to NS (and adjuvantly treated with drugs), 95.8 and 91.7% in those submitted to NS + RT (and drugs as well), 70.2 and 55.2% in those treated only with drugs (increased to 82.2 and 60.9% if considering only patients treated with modern long-acting drugs). Hypopituitarism had occurred in 25, 66.6, and 13.8% in the three groups, respectively. At multivariate analysis, previous RT and NS were significant positive predictors of cure, whereas previous NS, follow-up, and year of diagnosis were significant positive predictors of control. Diabetes was a negative predictor both of cure and control. Sex, age, baseline GH levels, hyperPRL, tumor size, extrasellar extension, and invasiveness were not independent predictors of either cure or control.


CONCLUSIONS
This series seems to indicate that a multimodal approach can achieve control of disease in most patients.
Attanasio
Roberto
R
Endocrinology, Istituto Ortopedico Galeazzi, Dr. Roberto Attanasio, via Compagnoni 1, Milano 20129, Italy. roberto.serena@libero.it
Montini
Marcella
M
Valota
Monia
M
Cortesi
Liana
L
Barbò
Regina
R
Biroli
Francesco
F
Tonnarelli
Giampiero
G
Albizzi
Mascia
M
Testa
Rosa Miranda
RM
Pagani
Giorgio
G
D000172:Acromegaly / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000236:Adenoma / Q000150:complications* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D054869:Clinical Audit; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D019382:Human Growth Hormone / Q000172:deficiency; D006801:Humans; D006966:Hyperprolactinemia / Q000209:etiology / Q000628:therapy; D007016:Hypophysectomy; D007018:Hypopituitarism / Q000209:etiology / Q000628:therapy; D007558:Italy; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D018491:Dopamine Agonists; D019382:Human Growth Hormone; D013004:Somatostatin
J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26
9768641
Endocrine. 2001 Jun;15(1):29-38
11572322
J Endocrinol Invest. 2004 Dec;27(11):1040-7
15754736
Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102
8050136
J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72
12915637
Endocr Pract. 2004 May-Jun;10(3):213-25
15382339
Lancet. 2001 Nov 24;358(9295):1754-9
11734231
Eur J Endocrinol. 1998 Nov;139(5):516-21
9849816
J Clin Endocrinol Metab. 2005 Feb;90(2):800-4
15562021
J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7
15070920
J Clin Endocrinol Metab. 2003 Sep;88(9):4193-8
12970286
J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12
12843150
Eur J Endocrinol. 2006 Feb;154(2):267-74
16452540
J Clin Endocrinol Metab. 2006 Jan;91(1):85-92
16263832
Ann Intern Med. 2003 Aug 5;139(3):194-204
12899587
J Neurosurg. 2006 Jun;104(6):899-906
16776333
J Clin Endocrinol Metab. 2003 Nov;88(11):5258-65
14602759
J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73
15886238
Clin Endocrinol (Oxf). 2002 Jan;56(1):73-7
11849249
Endocr Rev. 2007 Feb;28(1):20-47
16931767
Clin Endocrinol (Oxf). 2005 Mar;62(3):282-8
15730408
Clin Endocrinol (Oxf). 1996 Sep;45(3):291-8
8949566
J Clin Endocrinol Metab. 2005 Jul;90(7):4081-6
15886256
J Clin Endocrinol Metab. 2004 Feb;89(2):667-74
14764779
J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403
16449332
J Clin Endocrinol Metab. 2001 Nov;86(11):5240-4
11701684
J Clin Endocrinol Metab. 1998 Feb;83(2):374-8
9467544
J Clin Endocrinol Metab. 2000 Feb;85(2):526-9
10690849
J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75
16968795
J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8
15899958
Q J Med. 1970 Jan;39(153):1-16
5427331
Endocr Rev. 2004 Feb;25(1):102-52
14769829
J Clin Endocrinol Metab. 2004 Jun;89(6):2789-96
15181059
J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40
9745397
Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35
1355728
Eur J Endocrinol. 2004 Oct;151(4):439-46
15476442
Clin Endocrinol (Oxf). 2002 Jul;57(1):59-64
12100070
Eur J Endocrinol. 2005 Mar;152(3):379-87
15757854
Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90
10207690
N Engl J Med. 2000 Apr 20;342(16):1171-7
10770982
Endocrinol Metab Clin North Am. 1992 Sep;21(3):669-92
1521518
Q J Med. 1993 May;86(5):293-9
8327647
J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8
12843148
N Engl J Med. 2006 Dec 14;355(24):2558-73
17167139
Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15
15272916